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Summary
Principles:Data on changes of haemostatic pa-
rameters at altitudes above 5000 m are very lim-
ited. So far it is unknown, whether altered coagu-
lation could contribute to the development of
acute mountain sickness.
Methods: Thirty four healthy mountaineers
were randomised to two acclimatisation protocols
and undertook an expedition on Muztagh Ata
(7549 m) in China.Tests were performed at five al-
titudes up to 6865 m. Haemostatic parameters,
such as PT, aPTT, D-Dimer, APC-Resistance
(APCR), von Willebrand Factor activity (RCo),
ADAMTS-13 & C-Natriuretic Peptide (CNP)
were assessed together with Lake Louise AMS
score.
Results: D-Dimer significantly increased with
increasing altitude (median 0.62 to 0.81 mg/L,
p <0.0001). During ascent, PT increased (83% to
>100%) and APCR decreased significantly from
0.95 to 0.8 (p <0.01). Furthermore, a significant
increase of aPTT (38 to 43 sec) was paralleled by
significant changes of RCo (102% to 62%) (both
p <0.001). There were no significant changes in
ADAMTS-13 and CNP. No significant relation-
ship between investigated parameters and AMS
scores could be detected. When comparing the
participants of the two acclimatisation protocols,
there was an overall higher RCo in patients with a
faster ascent protocol (p = 0.04). This was accom-
panied by lower ADAMTS-13 of the coagulation
system in these patients (p = 0.04).
Conclusions: Coagulation parameters change
significantly during hypobaric hypoxia. Whereas
we could detect no association between AMS
scores and coagulation parameters, our results do
show some parameters to be associated with an ac-
climatisation protocol and a successful ascent to
the summit.
Key words: coagulation; high altitude expedition;
ADAMTS-13; von Willebrandt factor; APC-R.
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Introduction
Ascending to a high altitude greater than 8000
feet (2500 m) above sea level is associated with
acute mountain sickness (AMS) and more severe
conditions such as high altitude cerebral oedema
(HACE) and high altitude pulmonary oedema
(HAPE). AMS itself is characterised by headache,
anorexia, nausea, insomnia and malaise [1, 2].
The prevalence of AMS depends on the rate
of ascent, the altitude reached and individual sus-
ceptibility [3]. For the diagnosis of AMS the Lake
Louise Scoring Consensus Committee has de-
fined the acute mountain sickness score which can
be obtained with a questionnaire [4].
To date the detailed pathophysiological mech-
anisms of AMS,HAPE andHACE are not known.
However it is known that hypobaric hypoxia
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causes over perfusion of microvascular beds, ele-
vated pulmonary capillary pressure and capillary
leakage [5, 6]. Whether capillary leakage results
from increased shear stress or is due to reactive ox-
ygen species (ROS) or other as yet unknown
mechanisms is subject of further investigation.
In some way all these reactions to hypobaric
hypoxia indicate a critical change of interactions
within the vascular system. Several of the case re-
ports of venous thromboembolism in high altitude
mountaineers triggered scientific interest on clar-
ifying the role of coagulation in high altitude ill-
ness [7]. Further, some studies showing evidence
of procoagulatory activity under hypobaric hy-
poxia have been published [8, 9]. Singh and Cho-
han found increased plasma fibrinogen, platelet
adhesiveness, platelet factor 3, factor V, factor VIII
in subjects who developed high altitude pulmo-
nary hypertension [10]. Later P. Bärtsch et al.
could show that increased fibrinolytic activity did
not proceed to HAPE, even though they found an
association with procoagulant activity [11]. An-
drew et al published data on coagulation following
prolonged decompression in a large hypobaric
chamber.They found that chronic hypoxia did not
affect coagulation factors, whereas factor VIII in-
creased under exercise at all investigated atmos-
pheric pressures [12].
With this present study we aimed to define
the role of the coagulation system, vonWillebrand
Factor (vWF)-System and the vWF-cleaving pro-
tease (ADAMTS13) in acclimatisation as these
factors have been shown to be involved in micro-
thrombus formation and vessel wall alterations
[13, 14]. VWF is synthesized exclusively by en-
dothelial cells and megacaryocytes. It has further
been shown that increased concentrations of vWF
occur in different vascular diseases such as cere-
brovascular diseases, peripheral and pulmonal vas-
cular diseases [15].
ADAMTS13, a member of the ADAMTS
family of metalloproteases, is known to be in-
volved in microvascular diseases such as throm-
botic thrombocytopenic purpura (TTP) [16].
VWF is cleaved under shear stress byADAMTS13
[17]. Shear stress is also seen as a possible factor
leading to vessel alteration with consequent capil-
lary leakage and oedema. Finally, it could be dem-
onstrated that oxygen desaturation correlates sig-
nificantly with multimeric abnormalities of vWF
in patients with secondary pulmonary oedema.
This is mostly due to loss of larger vWF multi-
mers [18]. To date, however not much is known
about coagulation changes during ascent to high
altitudes, and whether changes in the coagulation
system could be associated with severity of acute
mountain sickness scores. We therefore investi-
gated changes in the coagulation system during a
research expedition on Mount Muztagh Ata.
Materials and methods
Course of expedition and subjects
This study was a project of the 2005 Swiss Research
Expedition on Mount Muztagh Ata (7549 m/24729 ft
above sea level) in Western China that took place from
14 June to 8 July 2005. The research expedition was a
joint research enterprise with other groups investigating
a) the effect of high altitude related hypoxia on cerebral
function; b) ventilation, sleep and daytime performance at
extreme altitude; and c) pathogenesis of high altitude
retinopathy during a high altitude expedition. Our group
focused on renal function, [19] coagulation parameters,
inflammation and cardiac adaptation to high altitude.
Volunteers were recruited for study inclusion in
Swiss newspapers. Inclusion criteria were previous trek-
king experience and previous sojourns at high altitude.
Subjects were excluded when there was evidence of any
type of cardiac or respiratory disease or regular intake of
any medication. Subjects with a history of high altitude
pulmonary oedema, severe acute mountain sickness at al-
titudes below 3500 m or high altitude cerebral oedema
were also included.Thirty four healthy mountaineers par-
ticipated and gave written informed consent. All of the
participants were lowland residents (400–500 m/1310–
1638 ft above sea level). The mountaineers were ran-
domised into two groups with different ascent protocols
(group 1: 9 days for acclimatisation at altitudes between
3750 to 5533 m; group 2: 13 days for acclimatisation at al-
titudes between 3750 to 5533 m) to explore a possible role
of acclimatisation. The expedition had its base camp at
4497 m / 14731ft above sea level. Further milestones of
the expedition were at 5533 m / 18125 ft (camp 1), at
6265 m / 20523 ft (camp 2), at 6865 m / 22488 ft (camp
3) and at 7546 m/24719 ft (Muztagh Ata mountain peak)
above sea level. After acclimatisation, the predefined pro-
tocol for the final ascent from base camp to the Muztagh
Ata mountain peak comprised two nights at camp 1, two
nights at camp 2, and one night at camp 3 before reaching
the summit of Muztagh Ata. At each camp, several medi-
cal tests were conducted. Medical testing was done by re-
searchers (n = 15) none of whom belonged to the group of
investigated individuals.The participants were allowed to
use pain medication (i.e., paracetamol, aspirin, ibuprofen
and mefenaminic acid) as required. If a patient displayed
the need for other drugs for altitude related sickness or
other medical reasons, the patient was accompanied to a
lower location and excluded from further study.A detailed
log book regarding the intake of drugs, including painkill-
ers, was kept during the expedition. NSARs, which inter-
fere with platelet function, were the most frequently used
medication.We did not expect interaction of the medica-
tion used with the study results because endothelial and
coagulation factor activation rather than platelet activa-
tion was the subject of our research. The study is in ac-
cordance with the declaration of Helsinki and has ap-
proval of the institutional review board of the University
of Zurich. There was no attempt to obtain ethical ap-
proval of the study by respective institutions in the host
country.
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Blood sampling and measurements
In both groups, blood samples were drawn at four al-
titudes (pre expedition, 450 m/1474 ft above sea level), at
base camp (day 6 and 7), at camp 1 (day 9 and 10) and
camp 2 (day 16 and 20). In addition, it was possible to ob-
tain blood samples from the mountaineers from group 1
at camp 3 (day 22).The blood specimens were taken after
at least one overnight rest after a camp has been reached.
The amount of blood we were able to draw at each alti-
tude was limited due to ethical consideration (fatigue) and
transport capacity. Venous blood was drawn using
20 gauge butterfly cannulae (Becton Dickinson, Basel,
Switzerland) and sterile tubes for collection of serum and
citrated plasma (Sarstedt, Sevelen, Switzerland). At each
altitude, the samples were centrifugated at 2300 G,
aliquoted immediately and kept frozen at ≤–20 °C until
analysis. In order to measure haematocrit by a mi-
cromethod, capillary blood samples were obtained
through puncture, aspiration and immediate centrifuga-
tion on site (Hettich, Bäch, Switzerland). Any medication
intake was recorded by the expedition physician. Lake
Louise acute mountain sickness score was assessed and
recorded daily at all levels [20]. Peripheral haemoglobin
oxygen saturation (SO
2
) was measured using a pulse
oxymeter (Onyx 9500, Nonin, Carouge, Switzerland).
Laboratory methods
Both aPTT [reference range 25–38 sec, interassay
variance 2.3–3.3%] and PT [reference range 14–20 sec,
interassay variance 1.9–3.1%] measurements were done
on citrated plasma using Platelin FS (Endotell, Basel,
Switzerland) and Inovin (Siemens, Düdingen, Switzer-
land). Both clotting times were measured on a CA-7000
(Sysmex, Horgen, Switzerland). Concentration of D-
Dimer [reference range <0.5 mg/l, interassay variance
2.7–5.8%] was measured in citrated plasma samples with
a latex-enhanced turbidimetric test for quantitative deter-
mination of cross-linked fibrin degradation products
(Behring Coagulation System, Dade Behring, Düdingen,
Germany) [21]. vWF-RCo [reference range 56–150%, in-
terassay variance 6.6%] was determined by an automated
system (BCS, Dade Behring, Marburg, Germany) which
utilises an agglutination of stabilised platelets in presence
of vWF. This induces a change in optical density that is
quantified by the coagulation analyser (Behring Coagula-
tion System, Dade Behring, Düdingen, Germany).
Activated protein C resistance (APC-R) was measured by
coagulation analyser [reference range >0.9, interassay var-
iance 5.7–7.9%] (BCS, Dade Behring, Düdingen, Ger-
many). All participants were genotyped for the presence
of Factor V Leiden and Prothrombin G20210A mutation
of the coagulation system.We also measured levels of C-
natriuretic peptide (CNP) [<10 µmol/l, interassay vari-
ance 9%] as an endothelial marker. NT-proCNP, as the
most stable fragment, was detected by a sandwich immu-
noassay using antibodies directed against specific amino
acids sequence [interassay variance 6.9–8.2%] [22]. BNP
[<33 ng/l, interassay variance 3.3–5.0%] and measured on
an Advia Centaur (Siemens Diagnostics, Zürich, Switzer-
land).ADAMTS 13 [>50%, interassay variance 7.5%] was
measured as described elsewhere [23]. A brief overview of
the investigated coagulation parameters is summarised in
table 1.
Statistical methods
Firstly, we investigated changes of the measured pa-
rameters during ascent.We then analysed whether the as-
cent protocol and the fact that the mountaineer reached
the mountain peak resulted in differences of the investi-
gated coagulation parameters. Finally, we investigated
whether there was an association between Lake Louise
AMS scores and the coagulation parameters. Changes in
all the different parameters at each altitude were investi-
gated using Friedman’s statistic followed by Dunn’s test.
Comparison between the two groups was done with the
Mann Whitney U-test. Correlations were calculated by
the nonparametric Spearman rank method.Calculation of
statistics and graphs were constructed by means of
GRAPHPAD PRISM,Version 4.03 (GraphPad Software,
San Diego, CA, USA) and SPSS 11.0.1 (Chicago, IL,
USA). Two-sided P-values <0.05 were assumed signifi-
cant.
Table 1
Overview of
the investigated
coagulation
parameters.
Parameter Description
aPTT Screening test measuring the intrinsic system of coagulation
PT Screening test measuring the extrinsic coagulation system
D Dimer Fibrin degradation product. Indirect measure of activated coagulation system
APC-R Anticoagulant response to activated Protein C may be diminished due to congenital (Factor V Leiden) or acquired
factors. Activated Protein C, together with Protein S inactivates procoagulant Factors V and VIII. Increased APC-
resistance (APC-R) leads to an increased risk for venous thromboembolic diseases
vWF Rco Measures activity of procoagulant vonWillebrand factor (vWF). Indicates qualitative or quantitative defects of vWF
ADAMTS 13
activity
Metalloprotease distributed by vessel wall,
Degrades procoagulant vonWillebrand factor (vWF) multimers, thereby reducing multimer activity
Results
Baseline characteristics and changes during
expedition
Thirty four volunteers were included in the
study, 18 of whomwere assigned to the group with
the faster acclimatisation period (group 1),whereas
16 were assigned to the group with a longer ascent
(group 2). The baseline participant characteristics
obtained prior to the expedition are given in
table 2.
As shown in figure 1a, D-Dimer concentra-
tions gradually increased with altitude, indicating
incrementing activation of coagulation whilst
reaching higher altitudes (p <0.001). The increase
of D-Dimer also remains significant when cor-
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recting D-Dimer concentrations for haem dilu-
tion, as assessed with the haematocrit (p <0.001).
During ascent, PT increased (p <0.001; fig. 1b)
andAPCR decreased significantly from 0.95 to 0.8
(p <0.001; fig. 1c), indicating procoagulant changes
in the protein C inactivation with increasing alti-
tude. Interestingly, a significant increase of aPTT
(p <0.001; fig. 1d) was paralleled by significant de-
creases of vonWillebrand factor (RCo) (p <0.001),
possibly indicating increased consumption of von
Willebrand Factor.The correlation of the relative
changes of RCo with the relative changes in PTT
was significant (r = –0.26; 95% CI –0.44 to –0.07;
p = 0.006). There were no significant changes in
ADAMTS-13 activity (p = 0.28) and CNP con-
centrations (p = 0.35).
Lake Louise AMS Score and influence
of different ascent protocols
When relating the investigated coagulation
parameters to AMS scores (table 3), no significant
correlation could be detected with any parameter.
Table 2
Baseline characteristics
of the two groups.
All subjects have been
checked for throm-
bophilia, such as Factor
V Leiden Mutation and
G20210A prothrombin
mutation. Two subjects
were found with a
heterozygote Faktor V
Leiden mutation.
Group 1
(shorter acclimatization period)
Group 2
(longer acclimatization period)
p-value
N 18 16
Gender (female/male) (3/15) (4/12) n.s.
Age, years (mean ± SD) 46 [31, 56] 46 [37, 51] n.s.
Reaching Muztagh Ata Peak 11/18 8/16 n.s.
Haematocrit 43 [41, 44] 43 [42, 45] n.s
PT, % 80 [77, 85] 87 [74, 100] n.s
aPTT, sec. 32.5 [30, 34] 33 [31.5, 36.5] n.s.
D-Dimer, mg/L 0.54 [0.35, 0.74] 0.62 [0.46, 0.71] n.s.
vWF-RCo, % 105 [74, 125] 100 [65, 129] n.s.
ADAMTS-13 61 [54, 73] 71 [54, 85] n.s.
CNP 2.18 [1.76, 5.18] 2.96 [1.73, 4.22] n.s.
APC-R, Index 0.84 [0.79, 0.87] 0.83 [0.72, 0.89] n.s.
Data are given as median and interquartile range [IQR].
Figure 1
Course of coagula-
tion parameters
during high altitude
expedition. First
sample taken pre
expedition (450 m
above sea level; 1474
ft), other samples
taken consecutively
at base camp (4497
m; 14731 ft), camp 1
(5533 m; 18125 ft),
camp 2 (6625 m;
20523 ft) and camp 3
(6885 m; 22488 ft).
Measurements were
compared using the
Friedman repeated
measures ANOVA on
ranks test.The levels
of a) D-Dimer concen-
trations (p <0.001),
b) prothrombin time
(PT) (p <0.001),
c) APC-resistance
(p <0.001), and
d) activated partial
thromboplastin time
(p <0.001) exhibited
signiﬁcant changes
and are shown at the
different altitudes.
At base camp, there
was a measurement
with substantially
prolonged aPTT.
The reason for this
ﬁnding remains
unclear, a review
of pre-analytical and
analytical procedures
reveal no causes for
such prolongation.
a) b)
d)c)
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When further comparing the participants of the
two acclimatisation protocols, there was an overall
higher RCo activity in mountaineers with a faster
ascent protocol (88%, interquartile range, IQR,
64–121%, vs 65%, IQR 43–106%, p = 0.04;
fig. 2). This might be partly explained by the fact
that overall ADAMTS-13 activity was lower in
those with a faster ascent protocol (62%, IQR 50–
79%, vs 72%, IQR 51–94%, p = 0.04). With re-
gard to the ascent protocol none of other investi-
gated parameters exhibited significant overall dif-
ferences.
Difference between mountaineers who reached
the summit and those who did not
Finally, we investigated whether levels of
coagulation parameters were associated with the
fact that a mountaineer was able to successfully
reach the mountain peak. Interestingly, overall,
mountaineers reaching Muztagh Ata mountain
peak had significantly lower D-Dimer concentra-
tions at baseline (0.48 mg/L, IQR 0.31–0.63 mg/L
vs 0.65 mg/L, IQR 0.53–0.95 mg/L; p = 0.04) and
overall (0.71 mg/L, IQR 0.46–0.89 mg/L vs 0.82
mg/L, IQR 0.66–1.17 mg/L; p <0.01) (fig. 3). Fur-
ther, mountaineers reaching Muztagh Ata moun-
tain peak overall had longer aPTT (44s, IQR 38-
71s, vs 41s, IQR 36-56s; p = 0.06) and lower AD-
AMTS-13 activity (59%, IQR 48–78% vs 72%,
IQR 60–92%; p <0.01) than mountaineers, who
had to stop ascent due to different reasons. Nei-
ther aPTT nor ADAMTS-13 activity exhibited
significant differences at baseline. In regard to
whether a mountaineer reached the mountain
peak, none of the other investigated parameters
exhibited significant overall differences.
Table 3
Lake Louise AMS
score, oxygen
saturation (SaO
2
)
and haematocrit
during expedition.
Lake Louise AMS
score
SaO
2
Haematocrit
Base camp, 4497 m / 14731 ft 2 [1, 2.5] 85 [83, 86] % 44 [43, 47] %
Camp 1, 5533 m / 18125 ft 2 [1, 3] 76 [71, 79] % 45 [44, 48] %
Camp 2, 6265 m / 20523 ft 1 [1, 3] 75 [68, 76] % 49 [48, 53] %
Camp 3, 6865 m / 22488 ft 1 [1, 2] 74 [70, 79] % –
Haematocrit could not be measured at Camp 3.
Figure 2
Course of von
Willebrand factor
activity (RCo)
during high altitude
expedition according
to ascent protocol.
There was a
signiﬁcant decrease
with increasing
altitude (p <0.001).
Mountaineers with
fast ascent protocol
overall had lower
RCo than mountain-
eers with fast ascent
protocol (p = 0.04).
Figure 3
Course of von
D-Dimer concentra-
tions during high
altitude expedition
according to whether
a mountaineer
reached Muztagh
Ata mountain peak.
There was a
signiﬁcant increase
with increasing
altitude (p <0.001).
Mountaineers
reaching the
mountain peak had
signiﬁcantly lower
D-Dimer concentra-
tions than mountain-
eers having to stop
ascent, both at
baseline before the
expedition (p = 0.04)
and overall (p <0.01).
Discussion
The present study could demonstrate an acti-
vation of coagulation while ascending to high alti-
tude, as D-Dimer concentrations, PT and APC-
resistance exhibited procoagulatory changes. Fur-
ther, an association of rapidity of ascent with levels
of ADAMTS 13 activity and Ristocetin Cofactor
activity could be detected. Finally, we could iden-
tify coagulation parameters which were associated
with the fact that a mountaineer reached the
mountain peak.
The fact that significant increase of aPTT is
accompanied by significant decrease of RCo dur-
ing ascent might suggest consumption of vWF.
Therefore we assumed an activation or disruption
of the endothelial structure. Interestingly, CNP,
an endothelial marker, did not show significant
change during ascent. Further,ADAMTS13 activ-
ity did not show significant changes during the ex-
pedition. In short, whereas vonWillebrand factor
activity is associated with changes in altitude, no
such relationship was found regarding CNP and
ADAMTS-13 levels.
We could identify a procoagulatory state with
increasing altitude, as reflected with increasing D-
116
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Dimer concentrations and APC-resistance (as in-
dicated by a decreased APC-R test result). Both
increasing D-Dimer concentrations andAPC-Re-
sistance have been shown to increase the risk for
venous thromboembolism [24]. Our study design
was not able to differentiate whether hypoxia or
exercise contributes to the procoagulant changes.
A study by De Loughery et al. investigated the in-
teraction between hypoxia and exercise and their
influence on coagulation tests [25]. It was found
that exercise induced a procoagulant change in co-
agulation factors which was reduced by hypoxia.
In our study, we could have supplied participants
with oxygen, in order to study the effect of pro-
longed hypoxia on exercise induced procoagulant
changes during mountain expeditions. However,
this was not done as supplying oxygen is not com-
mon practice on mountain expeditions to heights
of about 7000 m above sea level.
One might argue that since D-Dimer was
measured over a period of several weeks, it could
be possible that sea level D-Dimer shows day to
day fluctuations which are not associated with a
prothrombotic state. Higher within-person varia-
bility would bias research findings to the null hy-
pothesis of no association [26]. Sakkinen et al.
found the intraindividual variability statistics to be
similar to those of an emerging cardiovascular dis-
ease risk marker, high-sensitivity C-reactive pro-
tein or somewhat higher than those of the widely
used total cholesterol measurement [27].We think
that intraindividual variability of D-Dimer con-
centrations does not invalidate our findings.
The fact that increasing altitude leads to a
procoagulatory state raises the question of whether
persons with pre-existing thrombophilic disorders
such as Factor V Leiden mutation, the G20210A
prothrombin promoter polymorphism or defi-
ciencies of protein S or protein C levels might
have an increased risk for venous thromboembo-
lism during high altitude expedition. In high alti-
tude expeditions, additional factors that may raise
the risk of thrombotic event are common (diar-
rhoea, bad weather with immobilisation, long
travel). For mountaineers in whom thrombophilic
disorders might be a problem due to a positive
family history, we suggest examination for the
common thrombophilic conditions.
When looking at the impact of ascent proto-
col and differences among the investigated coagu-
lation parameters, there were different levels of
RCo and ADAMTS-13 activity, with higher RCo
and lower ADAMTS-13 activity in mountaineers
with a faster ascent protocol. Surprisingly, there
was no relationship between the investigated pa-
rameters and the AMS scores. Even though we
found some association in changes of coagulation
parameters with reaching the summit, causality is
hard to evaluate because of too many other factors
are involved (e.g., physical fitness, psychological
factors). Nevertheless, the fact that participants
reaching the summit had significantly lower D-
Dimer levels pre-expedition than those partici-
pants who were forced to stop ascent was very sur-
prising. This finding is difficult to interpret, but
could also be due to type 1 error.
In our view, the present study has two limita-
tions. Firstly, we could not draw enough blood
from the mountaineers to assess more factors of
the systems for coagulation and fibrinolysis. As a
consequence, the conclusions are limited to the
investigated parameters. Secondly, the study has a
relatively low number of study participants in
whom changes in coagulation parameters were as-
sessed and is much too underpowered to assess the
frequency of clinically manifest venous throm-
boembolism during high altitude expedition. As a
result of this, our reasoning on prophylactic meas-
ures for patients with pre-existing thrombophilic
defects remains speculative.
Despite this we could demonstrate significant
changes in the investigated coagulation parame-
ters during high altitude expedition. We can also
demonstrate that newer markers of the coagula-
tion system such as ADAMTS-13 or APCR are in-
volved in high altitude pathophysiology. It re-
mains unclear whether these changes are causative
or merely reflective of the decreased fitness to
reach a mountain peak. It might be possible that
high altitude expedition confers a procoagulatory
state that could pose an additional risk for venous
thromboembolism in people with pre-existing
thrombophilic disorders.
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